$270.02
1.560.58%
At close: -
$271.07
1.050.39%
After Hours: 7:06 PM EDT
Comments
Loading...
Alnylam Pharmaceuticals Earnings Estimates, EPS & Revenue | NASDAQ:ALNY | Benzinga
Alnylam Pharmaceuticals reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Earnings Date
May 1
EPS Estimate
$-0.530
Quarterly Revenue Estimate
$558.35M
Annual Revenue
(as of Dec 31)
(as of Dec 31)
$2.25B
Analyze the earnings history of Alnylam Pharmaceuticals using advanced sorting and filters.
| Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ALNY | Alnylam Pharmaceuticals | -$0.16 | -$0.53 | — | — | $494.33M | $558.35M | — | — | 05/01/2025 | Get Alert |
| ALNY | Alnylam Pharmaceuticals | -$0.77 | -$0.14 | $0.06 | 142.86% | $439.72M | $580.62M | $593.17M | 2.16% | 02/13/2025 | Get Alert |
| ALNY | Alnylam Pharmaceuticals | $1.74 | -$0.93 | -$0.50 | 46.24% | $750.53M | $533.10M | $500.92M | -6.04% | 10/31/2024 | Get Alert |
| ALNY | Alnylam Pharmaceuticals | -$1.62 | -$1.08 | $0.56 | 151.85% | $318.75M | $444.11M | $659.83M | 48.57% | 08/01/2024 | Get Alert |
| ALNY | Alnylam Pharmaceuticals | -$1.06 | -$1.18 | -$0.16 | 86.44% | $319.29M | $427.33M | $494.33M | 15.68% | 05/02/2024 | Get Alert |
| ALNY | Alnylam Pharmaceuticals | -$1.39 | -$1.33 | -$0.77 | 42.11% | $335.04M | $442.90M | $439.72M | -0.72% | 02/15/2024 | Get Alert |
| ALNY | Alnylam Pharmaceuticals | -$1.58 | -$1.36 | $1.74 | 227.94% | $264.31M | $401.03M | $750.53M | 87.15% | 11/02/2023 | Get Alert |
| ALNY | Alnylam Pharmaceuticals | -$2.03 | -$1.72 | -$1.62 | 5.81% | $224.82M | $331.73M | $318.75M | -3.91% | 08/03/2023 | Get Alert |
| ALNY | Alnylam Pharmaceuticals | -$1.49 | -$1.76 | -$1.06 | 39.77% | $213.26M | $312.26M | $319.29M | 2.25% | 05/04/2023 | Get Alert |
| ALNY | Alnylam Pharmaceuticals | -$1.74 | -$1.90 | -$1.39 | 26.84% | $258.54M | $313.13M | $335.04M | 7.00% | 02/23/2023 | Get Alert |
| ALNY | Alnylam Pharmaceuticals | -$1.59 | -$1.78 | -$1.58 | 11.24% | $187.63M | $293.03M | $264.31M | -9.80% | 10/27/2022 | Get Alert |
| ALNY | Alnylam Pharmaceuticals | -$1.30 | -$1.62 | -$2.03 | -25.31% | $220.55M | $255.88M | $224.82M | -12.14% | 07/28/2022 | Get Alert |
| ALNY | Alnylam Pharmaceuticals | -$1.64 | -$1.84 | -$1.49 | 19.02% | $135.77M | $243.02M | $213.26M | -12.25% | 04/28/2022 | Get Alert |
| ALNY | Alnylam Pharmaceuticals | -$1.60 | -$1.54 | -$1.69 | -9.74% | $163.56M | $233.62M | $258.54M | 10.66% | 02/10/2022 | Get Alert |
| ALNY | Alnylam Pharmaceuticals | -$1.58 | -$1.57 | -$1.51 | 3.82% | $125.85M | $218.69M | $187.63M | -14.20% | 10/28/2021 | Get Alert |
| ALNY | Alnylam Pharmaceuticals | -$1.67 | -$1.60 | -$1.30 | 18.75% | $103.96M | $193.18M | $220.55M | 14.17% | 08/03/2021 | Get Alert |
| ALNY | Alnylam Pharmaceuticals | -$1.52 | -$1.75 | -$1.64 | 6.29% | $99.48M | $168.74M | $177.57M | 5.23% | 04/29/2021 | Get Alert |
| ALNY | Alnylam Pharmaceuticals | -$1.98 | -$1.76 | -$1.60 | 9.09% | $71.68M | $146.07M | $163.56M | 11.98% | 02/11/2021 | Get Alert |
| ALNY | Alnylam Pharmaceuticals | -$1.50 | -$1.66 | -$1.58 | 4.82% | $70.06M | $120.75M | $125.85M | 4.23% | 11/05/2020 | Get Alert |
| ALNY | Alnylam Pharmaceuticals | -$1.83 | -$1.74 | -$1.67 | 4.02% | $44.71M | $99.48M | $103.96M | 4.51% | 08/06/2020 | Get Alert |
| ALNY | Alnylam Pharmaceuticals | -$1.73 | -$1.89 | -$1.52 | 19.58% | $33.29M | $91.56M | $99.48M | 8.65% | 05/06/2020 | Get Alert |
Alnylam Pharmaceuticals (ALNY) Earnings Per Share
Quarterly Earnings Surprise Amount
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q4 | 2025-02-13 | $0.06 | $-0.14 | 142.9 % |
| Q3 | 2024-10-31 | $-0.50 | $-0.93 | 46.2 % |
| Q2 | 2024-08-01 | $0.56 | $-1.08 | 151.8 % |
| Q1 | 2024-05-02 | $-0.16 | $-1.18 | 86.4 % |
Alnylam Pharmaceuticals (ALNY) Revenue
Quarterly Revenue Surprise Amount
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q4 | 2025-02-13 | $593.17M | $580.62M | 2.16 % |
| Q3 | 2024-10-31 | $500.92M | $533.10M | -6.04 % |
| Q2 | 2024-08-01 | $659.83M | $444.11M | 48.6 % |
| Q1 | 2024-05-02 | $494.33M | $427.33M | 15.7 % |
FAQ
When is Alnylam Pharmaceuticals (NASDAQ:ALNY) reporting earnings?
Alnylam Pharmaceuticals (ALNY) is scheduled to report earnings on May 1, 2025. The last reported earnings were for reported on February 13, 2025 for Q4.
What were the latest earnings per share (EPS) for Alnylam Pharmaceuticals (NASDAQ:ALNY)?
The Actual EPS was $0.06, which beat the estimate of $-0.14.
What were Alnylam Pharmaceuticals’s (NASDAQ:ALNY) revenues?
The Actual Revenue was $593.2M, which beat the estimate of $580.6M.
Browse earnings estimates, EPS, and revenue on all stocks.